Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension. The company is also developing OTX-TIC, an intracameral travoprost implant for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; and OTX-TKI, a tyrosine kinase inhibitor intravitreal injection that delivers a hydrogel-based anti-angiogenic formulation for the treatment of wet age-related macular degeneration. In addition, it markets ReSure Sealant, a hydrogel-based ophthalmic wound sealant to seal corneal incisions following cataract surgery. Further, the company engages in the preclinical development of formulations of its hydrogel administered via intravitreal injection to address the diseases and conditions of the back of the eye. Ocular Therapeutix, Inc. has collaboration agreement with Regeneron Pharmaceuticals, Inc. for the development and commercialization of products using its hydrogel in combination with large molecule VEGF-targeting compounds for the treatment of retinal diseases. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OCUL
CUSIPN/A
Phone781-357-4000
Debt
Debt-to-Equity Ratio0.22
Current Ratio4.90
Quick Ratio4.89
Price-To-Earnings
Trailing P/E Ratio-3.40
Forward P/E Ratio-4.68
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.92 million
Price / Sales146.21
Cash FlowN/A
Price / CashN/A
Book Value$0.72 per share
Price / Book10.46
Profitability
EPS (Most Recent Fiscal Year)($2.20)
Net Income$-63,380,000.00
Net Margins-3,418.79%
Return on Equity-153.53%
Return on Assets-88.54%
Miscellaneous
Employees119
Outstanding Shares37,280,000
Ocular Therapeutix (NASDAQ:OCUL) Frequently Asked Questions
What is Ocular Therapeutix's stock symbol?
Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."
How were Ocular Therapeutix's earnings last quarter?
Ocular Therapeutix Inc (NASDAQ:OCUL) issued its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by $0.02. The biopharmaceutical company had revenue of $0.34 million for the quarter. Ocular Therapeutix had a negative net margin of 3,418.79% and a negative return on equity of 153.53%. View Ocular Therapeutix's Earnings History.
When is Ocular Therapeutix's next earnings date?
What price target have analysts set for OCUL?
5 brokerages have issued 1-year target prices for Ocular Therapeutix's shares. Their forecasts range from $8.00 to $22.00. On average, they expect Ocular Therapeutix's share price to reach $13.00 in the next twelve months. View Analyst Ratings for Ocular Therapeutix.
What are Wall Street analysts saying about Ocular Therapeutix stock?
Here are some recent quotes from research analysts about Ocular Therapeutix stock:
- 1. HC Wainwright analysts commented, "We continue to believe that Dextenza has the potential to obtain regulatory approval in the U.S. by the end of 2018 and start generating revenue around mid-2019. The company plans to apply for a pass-through reimbursement status (C code) for Dextenza. With bundled pricing of cataract surgery, Dextenza should be priced above $480 per dose according to CMS guidelines, in our view. In the wake of this update, we reiterate our Buy rating and $10 price target." (6/21/2018)
- 2. According to Zacks Investment Research, "Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts. " (5/25/2018)
- 3. BTIG Research analysts commented, "On Thursday, before market open, the management team of Ocular Therapeutix hosted their 4Q17 earnings call. We think the updates provided on the call were in line with expectations. The company expects to resubmit the Dextenza NDA during 1H2018, with an FDA decision likely by YE2018. Key leadership positions have also been filled including the hiring of experienced quality and regulatory personnel, which we think could further provide additional investor confidence moving forward. We reiterate our Buy rating and $9 Price Target." (3/11/2018)
- 4. Cantor Fitzgerald analysts commented, "Potential Approval before The End of The Year. After receiving feedback earlier this year, Ocular believes the complete and clear nature of the FDA’s responses removes the need for a meeting to obtain additional feedback. Currently, the company is conducting on-going manufacturing runs in order to establish and support confidence limits for particulate observed. Based on the focus on manufacturing, we anticipate a Type 2 review, consistent with a manufacturing inspection and six month review timeline." (3/8/2018)
Who are some of Ocular Therapeutix's key competitors?
Some companies that are related to Ocular Therapeutix include Alder Biopharmaceuticals (ALDR), Revance Therapeutics (RVNC), Eagle Pharmaceuticals (EGRX), Retrophin (RTRX), TG Therapeutics Inc common stock (TGTX), Esperion Therapeutics (ESPR), Flexion Therapeutics (FLXN), Epizyme (EPZM), Intra-Cellular Therapies (ITCI), OptiNose (OPTN), Vanda Pharmaceuticals (VNDA), Dynavax Technologies (DVAX), Wave Life Sciences (WVE), Reata Pharmaceuticals (RETA) and MacroGenics (MGNX).
Who are Ocular Therapeutix's key executives?
Ocular Therapeutix's management team includes the folowing people:
- Dr. Amarpreet Sawhney, Founder & Exec. Chairman (Age 51)
- Mr. Antony Mattessich, Pres, CEO & Director (Age 51)
- Mr. Donald Notman Jr., Chief Financial Officer
- Dr. Michael H. Goldstein, Chief Medical Officer (Age 51)
- Mr. Kevin F. Hanley, Sr. VP of Technical Operations (Age 56)
Has Ocular Therapeutix been receiving favorable news coverage?
Media headlines about OCUL stock have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Ocular Therapeutix earned a media sentiment score of 0.08 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 45.95 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Ocular Therapeutix's major shareholders?
Ocular Therapeutix's stock is owned by many different of retail and institutional investors. Top institutional investors include Summer Road LLC (8.12%), BlackRock Inc. (4.55%), Deltec Asset Management LLC (1.57%), Northern Trust Corp (0.87%), Schwab Charles Investment Management Inc. (0.14%) and California State Teachers Retirement System (0.12%). Company insiders that own Ocular Therapeutix stock include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag and Donald Notman. View Institutional Ownership Trends for Ocular Therapeutix.
Which major investors are selling Ocular Therapeutix stock?
Which major investors are buying Ocular Therapeutix stock?
OCUL stock was acquired by a variety of institutional investors in the last quarter, including Summer Road LLC, Deltec Asset Management LLC, BlackRock Inc., Northern Trust Corp, Barclays PLC, Millennium Management LLC, The Manufacturers Life Insurance Company and GSA Capital Partners LLP. Company insiders that have bought Ocular Therapeutix stock in the last two years include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag and Donald Notman. View Insider Buying and Selling for Ocular Therapeutix.
How do I buy shares of Ocular Therapeutix?
Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ocular Therapeutix's stock price today?
One share of OCUL stock can currently be purchased for approximately $7.53.
How big of a company is Ocular Therapeutix?
Ocular Therapeutix has a market capitalization of $289.85 million and generates $1.92 million in revenue each year. The biopharmaceutical company earns $-63,380,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis. Ocular Therapeutix employs 119 workers across the globe.
How can I contact Ocular Therapeutix?
Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at 781-357-4000 or via email at [email protected]
MarketBeat Community Rating for Ocular Therapeutix (OCUL)
MarketBeat's community ratings are surveys of what our community members think about Ocular Therapeutix and other stocks. Vote "Outperform" if you believe OCUL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCUL will underperform the S&P 500 over the long term. You may vote once every thirty days.
